OESOPHAGEAL CANCER (OC) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK Did you know?

Globally, OC accounted for nearly **511,000 new cases in 2022**


Globally, Oesophageal Cancer is the 11th most diagnosed cancer and the 7th most leading cause of cancer mortality

Asia had the highest incidence cases and accounted for nearly 70% of the global incidence cases of OC

Europe had the **second highest incidence**, with over **53,500 cases**

North America had more than 21,800 cases, followed by rest of the world (ROW)

TRIAL CONTRIBUTIONS





Countries like Mainland China, the United States, South Korea, and Spain emerged as top locations for

conducting trials



Asia-Pacific showed faster recruitment durations and patient recruitment rates



The OC treatment market offers diverse products by companies including Advanz Pharma Corp. Ltd, BeiGene Ltd., InnoKeys Pte. Ltd. and Simcere Pharmaceutical Group Ltd



Multiple ongoing **Phase III trials** demonstrate continued efforts to enhance **OC treatment through antibody, small molecule, bispecific or multispecific antibody and peptide vaccine therapies**

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com